



Enanta
Pharmaceuticals
Great Chemistry Cures


**Zelicapavir Decreases Symptom Duration,
Hospitalization, and Viral Load in a Global,
Randomized, Double-Blinded, Placebo-Controlled
Phase 2 Trial of High-Risk Adults with RSV**

C. Harris, J. DeVincenzo, S. Chen, T. Ngo, A. Ahmad, M. Turnak, S. Rottinghaus
Enanta Pharmaceuticals - Watertown, Massachusetts (United States)

ESCMID Global 2026; April 18, 2026; Munich, Germany

Zelicapavir (EDP-938): N-Protein Inhibitor for RSV


- N-inhibitor in clinical development for RSV
 - Replication inhibitor: shuts down the production of new virions (vs. fusion inhibitors that block viral entry)
- Granted Fast Track designation by the FDA
- Strong preclinical profile
 - Nanomolar potency against RSV-A and RSV-B
 - Antiviral potency across all clinical isolates tested
 - High barrier to resistance
 - Synergistic activity and no cross-resistance with other drug mechanisms (e.g. L-inhibitors)
- Favorable safety and efficacy profile in clinical studies
 - Challenge study showed reduction in viral load and clinical symptoms
 - Pediatric study showed reduction in viral load and clinical symptoms
 - Well-tolerated in more than 700 people dosed



Zelicapavir Phase 2b RSV High-Risk Adult Study: Design & Objectives

186 adults with at least one of the following:

- COPD
- Congestive heart failure
- Asthma
- Age ≥ 65



- Patients enrolled within 72 hours of RSV symptom onset
- Patients with only high risk criterion of either age 65-74 or asthma capped at 20% of the total
- ▶ **HR3 = ~80% of the population with CHF, COPD, or age ≥ 75**


- **Primary Objective:**
Time to resolution** of RSV LRTD symptoms (RiiQ™ symptom scale)
 - Shortness of breath, wheezing, coughing, coughing up phlegm
- **Secondary Objectives:**
PROs, MAVs, virology, antibiotic use, bronchodilator use, corticosteroid use, hospitalization, ICU, mechanical ventilation, all cause mortality, PK & safety

First proof-of-concept Phase 2 high-risk adult outpatient study with positive clinical signal

*Equivalent to 600mg suspension dosage form used in challenge study; **Resolution: all symptoms mild or absent

COPD: chronic obstructive pulmonary disease; LRTD: lower respiratory tract disease; PROs: patient reported outcomes; MAVs: medically attended visits; ICU: intensive care unit; PK: pharmacokinetics; QD: once-daily

Zelicapavir Phase 2b RSV High-Risk Adult Study: Patient Disposition



*One patient randomized to zelicapavir was treated with placebo in error. Data for this patient are in the placebo group for safety analyses and zelicapavir group for efficacy analyses.

One patient withdrew consent after 5 doses. One patient withdrew consent after 1 dose. One patient discontinued study after 1 dose due to SAE. One patient died after completing 5 doses.

Four patients withdrew consent after 5 doses. One patient withdrew consent after 2 doses. One patient withdrew consent after 1 dose.

Zelicapavir Phase 2b RSV High-Risk Adult Study: Baseline Characteristics (Safety & HR3 Population)



- Baseline characteristics were balanced across treatment groups
- Majority of patients (~2/3) enrolled within 48 hours of symptom onset prior to randomization

Description	Safety Population		HR3 Population*	
	Zelicapavir (N=121)	Placebo (N=65)	Zelicapavir (N=92)	Placebo (N=50)
Age: Years – Median (Min, Max)	71 (29, 97)	72 (24, 96)	73 (29, 97)	73 (36, 96)
Sex: Female – n (%)	74 (61.2)	49 (75.4)	52 (56.5)	38 (76.0)
Race: White – n (%)	101 (83.5)	57 (87.7)	79 (85.9)	45 (90.0)
Did Not Receive RSV Vaccination – n (%)	120 (99.2)	64 (98.5)	91 (98.9)	49 (98.0)
Duration of RSV Symptoms Prior to Randomization ≤ 48 hours	78 (64.5)	42 (64.6)	58 (63.0)	32 (64.0)

*HR3 Population = Patients with CHF, COPD, or age ≥75

Zelicapavir Phase 2b RSV High-Risk Adult Study: Baseline Characteristics (Safety & HR3 Population)



- Baseline characteristics were balanced across treatment groups

Description	Safety Population		HR3 Population*	
	Zelicapavir (N=121)	Placebo (N=65)	Zelicapavir (N=92)	Placebo (N=50)
CHF – n (%)	27 (22.3)	8 (12.3)	26 (28.3)	8 (16.0)
COPD – n (%)	45 (37.2)	25 (38.5)	43 (46.7)	24 (48.0)
Asthma – n (%)	32 (26.4)	16 (24.6)	13 (14.1)	9 (18.0)
Total RSV Symptom Score (RiiQ™; RSV 13-symptoms each scored 0-3)				
n	120	64	91	49
Mean (SD)	1.50 (0.507)	1.46 (0.479)	1.46 (0.484)	1.46 (0.445)
RSV Viral Load by RT-qPCR (log ₁₀ copies/mL)				
n	112	58	88	47
Mean (SD)	5.31 (1.958)	5.36 (2.174)	4.99 (2.065)	5.28 (2.160)

*HR3 Population = Patients with CHF, COPD, or age ≥75

Zelicapavir Phase 2b RSV High-Risk Adult Study: Favorable Safety Profile




- Adverse events (AEs) were similar between zelicapavir dosing groups and placebo
- No AEs led to treatment discontinuation or study withdrawal in zelicapavir group

Description	Zelicapavir (N=121)	Placebo (N=65)
Treatment emergent AEs (TEAEs)	27 (22.3%)	16 (24.6%)
Study drug related TEAEs	7 (5.8%)	3 (4.6%)
Grade 3 or higher TEAEs	1 (0.8%)	5 (7.7%)
Serious TEAEs	2 (1.7%)	4 (6.2%)
TEAEs leading to study drug discontinuation	0	1 (1.5)
TEAEs leading to study withdrawal	0	2 (3.1)
TEAEs leading to death	0	1 (1.5)

Zelicapavir Phase 2b RSV High-Risk Adult Study:

Faster Time to Complete Symptom Resolution Across Multiple RiiQ™ Measures



*HR3 Population: Patients with CHF, COPD, or age ≥ 75 ; LRTD: lower respiratory tract disease

Zelicapavir Phase 2b RSV High-Risk Adult Study: Symptom Summary for Zelicapavir Compared to Placebo

Symptoms Measured by RiiQ™

- Faster time to complete resolution of all RSV symptoms to absent
 - Symptom reduction of ~one week in the HR3 population for all 13 RSV symptoms and total RiiQ
- No effect on time to resolution of RSV symptoms to mild, including primary endpoint (time to resolution of LRTD subset of symptoms to mild in the efficacy population)
- Improvement in RSV 13-symptom score* in HR3 population
 - Day 9 (p=0.0403) and Day 14 (p=0.0247)

Symptom Resolution Measured by PGI-S

- 2-day faster median time to improvement in efficacy (p=0.0446) and HR3 population (p=0.0465)

*post-hoc analysis

RiiQ: Respiratory Infection Intensity and Impact Questionnaire; PGI-S: Patient Global Impression of Severity; HR3 Population: Patients with CHF, COPD, or age ≥ 75 ; LRTD: lower respiratory tract disease

Zelicapavir Phase 2b RSV High-Risk Adult Study: Hospitalization and Death Endpoints

- Lower hospitalization rate for patients treated with zelicapavir


	Placebo	Zelicapavir
All-cause-hospitalizations	5.0% (3/60)	1.7% (2/115)
RSV-associated hospitalizations <ul style="list-style-type: none">• Blinded investigator attribution	5.0% (3/60)	0% (0/115)

- One death on placebo; no deaths on zelicapavir

Zelicapavir Phase 2b RSV High-Risk Adult Study: Virology Results for Zelicapavir Compared to Placebo

- **Larger viral load decline at end of treatment (Day 5)**
 - Efficacy Population: 0.6 log
 - HR3 population: 0.7 log
- **Greater proportion of patients with undetectable viral load at the end of treatment**
 - Efficacy Population: 23.5% (27/115) vs 10.0% (6/60) (p=0.0198)
 - HR3 Population: 23.9% (22/92) vs 10.0% (5/50) (p=0.0292)
- **Faster median time to undetectable viral load**
 - Efficacy Population: 4 days
 - HR3 Population: 5 days

RSV PCR viral load decline of **0.7 log** for HR3 population at the end of treatment



Zelicapavir Phase 2b RSV High-Risk Adult Study: Pharmacokinetics

- Zelicapavir target exposures were achieved, and were consistent with exposures observed in previously treated subjects
- Mean predose (C_{trough}) concentrations were 1100 and 1141 ng/mL on Days 3 and 5, respectively

Visit	n	Mean	% CV
Day 3	101	1100	79
Day 5	104	1141	65

- Mean C_{trough} concentrations were 55-fold and 57-fold higher than the *in vitro* EC_{90} (20 ng/mL) for RSV M37, on Days 3 and 5 respectively

Zelicapavir Phase 2b RSV High-Risk Adult Study:

Conclusions

- Zelicapavir demonstrated compelling results on multiple clinically meaningful endpoints measuring different aspects of RSV disease
 - ✓ Up to one week improvement in complete symptom resolution
 - ✓ Statistically significant improvement in PGI-S
 - ✓ Lower hospitalization rate
- Robust antiviral effect
- Favorable safety profile

Data support advancement of zelicapavir into Phase 3 study of high-risk adults